Transcriptome Study of Acute Myocardial Infarction

July 12, 2017 updated by: Yan Li, Beijing Institute of Heart, Lung and Blood Vessel Diseases

Screening Pathogenic Genes Associated With Acute Myocardial Infarction and Studying Its Relevant Molecular Mechanism

This study aims to compare whole-blood microarray gene-expression profiling between patients with acute myocardial infarction and normal participants without cardiovascular diseases. Firstly, screening differentially genes of mRNA to perform gene ontology and pathway analysis. Secondly, predicting target genes regulated by microRNA and constructing coexpression network with mRNA. Thirdly, biological function experiment of microRNA. Finally, revealing pathogenic mechanisms associated with acute myocardial infarction.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chaoyang
      • Beijing, Chaoyang, China, 100029
        • Recruiting
        • Beijing Anzhen Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

AMI patients will be selected from Emergency Department of Beijing An Zhen Hospital or Beijing Tong Ren Hospital.

Normal control participants will be recruited from Health Examination Center of Beijing An Zhen Hospital.

Description

Inclusion Criteria:

  • AMI patients:

    1. 20-50 years of age
    2. Symptoms of ischaemia
    3. New significant ST-segment-T wave changes in ECG and definitive diagnosis of non-ST elevation MI or ST elevation MI
    4. Cardiac troponin with at least one value above the 99th percentile upper reference limit

  • Normal control participants:

    1. 20-50 years of age
    2. Normal ECG
    3. BMI <24kg/m2
    4. systolic blood pressure <140mmHg
    5. diastolic blood pressure <90mmHg
    6. Total cholesterol <200mg/dl (5.18mmol/L)
    7. Triglyceride <150mg/dl (1.70mmol/L)
    8. High density lipoprotein cholesterol >=40mg/dl (1.04mmol/L)
    9. Low density lipoprotein cholesterol <130mg/dl (3.37mmol/L)
    10. Fasting blood glucose <100mg/dl (5.6mmol/L)
    11. Not taking antihypertensive or hypolipidemic or hypoglycemic drugs

Exclusion Criteria:

  1. Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased
  2. Prior myocardial infarction
  3. Percutaneous coronary intervention related MI
  4. Stent thrombosis associated with MI
  5. Coronary artery bypass grafting related MI
  6. Recurrent MI or reinfarction
  7. Myocardial injury with necrosis caused by transcatheter aortic valve implantation or mitral clip or ablation of arrhythmias
  8. Myocardial injury or infarction associated with heart failure
  9. Myocardial infarction in the intensive care unit
  10. Other diseases: previous history of ASCVD, cancer, rheumatoid arthritis, liver or kidney disease, myeloproliferative disorders, chronic inflammation, peripheral vascular disease
  11. Not available informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Control
AMI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of screening differentially expressed genes associated with acute myocardial infarction as measured by microarray
Time Frame: up to 3 years
up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2017

Primary Completion (Anticipated)

December 31, 2019

Study Completion (Anticipated)

December 31, 2019

Study Registration Dates

First Submitted

May 15, 2017

First Submitted That Met QC Criteria

May 17, 2017

First Posted (Actual)

May 18, 2017

Study Record Updates

Last Update Posted (Actual)

July 14, 2017

Last Update Submitted That Met QC Criteria

July 12, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 5172011

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myocardial Infarction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe